We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis (CONSONANCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03523858
Recruitment Status : Active, not recruiting
First Posted : May 14, 2018
Last Update Posted : January 17, 2023
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Tracking Information
First Submitted Date  ICMJE April 16, 2018
First Posted Date  ICMJE May 14, 2018
Last Update Posted Date January 17, 2023
Actual Study Start Date  ICMJE May 28, 2018
Estimated Primary Completion Date January 15, 2026   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 4, 2020)
  • Proportion of Participants with No Evidence of Progression (NEP) [ Time Frame: From Baseline to Week 96, Week 96 to Week 192 and Baseline to Week 192 ]
    NEP is defined as no progression sustained for at least 24 weeks on all of the following three components (confirmed disability progression [CDP]; ≥20% increase in timed 25-foot walk test [T25FWT]; ≥20% increase in nine-hole peg test [9HPT])
  • Proportion of Participants with no evidence of progression and no active disease (NEPAD) [ Time Frame: From Baseline to Week 96, Week 96 to Week 192 and Baseline to Week 192 ]
    NEPAD is defined as no progression sustained for at least 24 weeks on all of the three components of NEP (CDP, T25FWT, 9HPT), no protocol-defined relapse, no enlarging or new T2 lesion, and no T1 gadolinium (Gd+)-enhancing lesion
Original Primary Outcome Measures  ICMJE
 (submitted: May 10, 2018)
  • Proportion of Participants with No Evidence of Progression (NEP) [ Time Frame: Baseline to Week 192 ]
    NEP is defined as no progression sustained for at least 24 weeks on confirmed disability progression (CDP, as measured by the EDSS), ≥20% increase in timed 25-foot walk test (T25FWT), and ≥20% increase in nine-hole peg test (9HPT).
  • Proportion of Participants with NEP Sustained For At Least 24 Weeks and No Active Disease (NEPAD) [ Time Frame: Baseline to Week 192 ]
    NEPAD is defined as no progression on all of the three components of NEP (CDP as measured by the EDSS), no protocol-defined relapse, no enlarging or new T2 lesion, and no T1 gadolinium (Gd)-enhancing lesion
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 11, 2021)
  • Change from Baseline in Cognitive Function, as Measured by the Symbol Digit Modalities Test (SDMT) [ Time Frame: Baseline to end of study (Week 192) ]
  • Change from Baseline in Cognitive Function, as Measured by Brief Visuospatial Memory Test - Revised (BVMT-R) [ Time Frame: Baseline to end of study (Week 192) ]
  • Mean Change from Baseline in the Expanded Disability Status Scale (EDSS) score over the course of the study [ Time Frame: Baseline to end of study (Week 192) ]
  • Time to Onset of First Confirmed Disability Progression (CDP) Sustained for at least 24 and 48 Weeks [ Time Frame: Baseline to onset of first CDP (as measured by EDSS) sustained for at least 24 and 48 weeks ]
  • Time to Onset of First >=20% Increase in Timed 25-foot Walk Test (T25FWT) Sustained for at least 24 Weeks [ Time Frame: Baseline to onset of first >=20% increase in T25FWT sustained for at least 24 weeks ]
  • Time to Onset of First >=20% Increase in 9 Hole Peg Test (9HPT) Sustained For At Least 24 Weeks [ Time Frame: Baseline to onset of first >=20% increase in 9HPT sustained for at least 24 weeks ]
  • Proportion of Participants with NEP [ Time Frame: Week 24 to Week 96, Week 24 to Week 192, and Week 48 to Week 192 ]
  • Proportion of Participants with NEPAD [ Time Frame: Week 24 to Week 96, Week 24 to Week 192, Week 48 to Week 192 ]
  • Change from Baseline in Patient-Reported Outcomes (PROs) [ Time Frame: Baseline to end of study (Week 192) ]
    PROs collected in this study will be the Multiple Sclerosis Impact Scale (MSIS-29), the Multiple Sclerosis Walking scale (MSWS-12), the ABILHAND-56 Questionnaire, Fatigue Scale for Motor and Cognitive function (FSMC), SymptoMScreen, 88-item Multiple Sclerosis Spasticity Scale (MSSS-88), Numerical Pain Rating Scale (NPRS), and the Patient Global Impression of Severity (PGIS) for upper limb, lower limb and cognitive function
  • Change from Baseline in the number of falls and near-falls [ Time Frame: Baseline to end of study (Week 192) ]
  • Change in Whole Brain Volume (Whole, Cerebral White Matter, Cortical Grey Matter, Deep grey matter) [ Time Frame: Baseline to end of study (Week 192) ]
  • Change in thalamic volumes [ Time Frame: Baseline to end of study (Week 192) ]
  • Change in whole and regional cerebellar volume (cervical cord grey and white matter area) [ Time Frame: Baseline to end of study (Week 192) ]
  • Change in cervical cord cross-sectional area (total, white matter and grey matter) [ Time Frame: Baseline to end of study (Week 192) ]
  • Change in number of new/enlarging T2 lesions and total T2 Lesion Volume [ Time Frame: Baseline to end of study (Week 192) ]
  • Change in number of T1 Gadolinium (Gd)+ Lesions and total volume [ Time Frame: 'Baseline to end of study (Week 192) ]
  • Change in number of T1 lesions [ Time Frame: Baseline to end of study (Week 192) ]
  • Number in total volume of T1 lesions [ Time Frame: Baseline to end of study (Week 192) ]
  • Change in Slowly Evolving Lesions (SEL) [ Time Frame: Baseline to end of study (Week 192) ]
  • Change in normalised T1 intensity/T1 Gd+ enhancement in New Focal T2 Lesions, SELs, Persistent Areas of Non-SEL T2 Lesions, and Normal-Appearing Brain Tissue [ Time Frame: Baseline to end of study (Week 192) ]
  • Change in Gd-enhancing late-Fluid-Attenuated Inversion-Recovery (FLAIR) Meningeal Lesions [ Time Frame: Baseline to end of study (Week 192) ]
  • Change in the number/ spatial distribution of lesions in the cervical spinal cord [ Time Frame: Baseline to end of study (Week 192) ]
  • Spectroscopic MR: Measure of the Relative Signal Amplitude of N-Acetyl Aspartate (NAA), and Choline to Creatine [ Time Frame: Baseline to end of study (Week 192) ]
    Only in centers with 1.5-Tesla MRI capable to perform it
  • Measure of phase rim lesions using a Susceptibility-Weighted Imaging [SWI]/T2 sequence [ Time Frame: Baseline to end of study (Week 192) ]
    Only in centers with 3-Tesla MRI capable to perform it, where this sequence would replace the spectroscopic MR in the acquisition flow
  • Percentage of Participants with Adverse Events (AEs) [ Time Frame: Baseline to end of study (Week 192) ]
  • Rates of study treatment discontinuation due to adverse events [ Time Frame: Baseline to Week 192 ]
Original Secondary Outcome Measures  ICMJE
 (submitted: May 10, 2018)
  • Change from Baseline in Cognitive Function, as Measured by the Symbol Digit Modalities Test (SDMT) [ Time Frame: Baseline to end of study (Week 192) ]
  • Change from Baseline in Patient-Reported Outcomes (PROs) [ Time Frame: Baseline to end of study (Week 192) ]
    PROs collected in this study will be the Multiple Sclerosis Impact Scale (MSIS-29), the Multiple Sclerosis Walking scale (MSWS-12), the ABILHAND Questionnaire, and the Fatigue Scale for Motor and Cognitive function (FSMC)
  • Mean Change from Baseline in the Expanded Disability Status Scale (EDSS) score over the course of the study [ Time Frame: Baseline to end of study (Week 192) ]
  • Time to Onset of First Confirmed Disability Progression (CDP) Sustained For At Least 24 Weeks [ Time Frame: Baseline to onset of first CDP (as measured by EDSS) sustained for at least 24 weeks ]
  • Time to Onset of First >=20% Increase in Timed 25-foot Walk Test (T25FWT) Sustained For At Least 24 Weeks [ Time Frame: Baseline to onset of first >=20% increase in T25FWT sustained for at least 24 weeks ]
  • Time to Onset of First >=20% Increase in 9 Hole Peg Test (9HPT) Sustained For At Least 24 Weeks [ Time Frame: Baseline to onset of first >=20% increase in 9HPT sustained for at least 24 weeks ]
  • Proportion of Participants with NEP [ Time Frame: Week 24 to Week 96, Week 24 to Week 192, and Week 48 to Week 192 ]
  • Proportion of Participants with NEPAD [ Time Frame: Week 24 to Week 96, Week 24 to Week 192, Week 48 to Week 192 ]
  • Time to Treatment or Study Discontinuation [ Time Frame: Baseline to week 192 ]
  • Change in Whole Brain Volume [ Time Frame: Baseline to end of study (Week 192) ]
  • Change in Cortical Gray Matter Volume [ Time Frame: Baseline to end of study (Week 192) ]
  • Change in Total T2 Lesion Volume [ Time Frame: Baseline to end of study (Week 192) ]
  • Change in Slowly Evolving Lesions (SEL) [ Time Frame: Baseline to end of study (Week 192) ]
  • Change in Total T1 Gadolinium (Gd)+ Lesion [ Time Frame: 'Baseline to end of study (Week 192) ]
  • Measurement of T1 Gd-enhancement in New Focal T2 Lesions, SELs, Persistent Areas of Non-SEL T2 Lesions, and Normal-Appearing Brain Tissue [ Time Frame: Baseline to end of study (Week 192) ]
  • Change in Cerebral White Matter Volume [ Time Frame: Baseline to end of study (Week 192) ]
  • Change in Gd-enhancing Fluid-Attenuated Inversion-Recovery (FLAIR) Meningeal Lesions [ Time Frame: Baseline to end of study (Week 192) ]
  • Spectroscopic MR: Measure of the Relative Signal Amplitude of N-Acetyl Aspartate (NAA), and Choline to Creatine [ Time Frame: 'Baseline to end of study (Week 192) ]
    Only in centers with 1.5-Tesla MRI capable to perform it
  • Measure of Phase Rim Lesions by T2* [ Time Frame: 'Baseline to end of study (Week 192) ]
    Only in centers with 3-Tesla MRI capable to perform it, where this sequence would replace the spectroscopic MR in the acquisition flow
  • Change in Brain Tissue Integrity as Measured by Signal Mass Analysis [ Time Frame: 'Baseline to end of study (Week 192) ]
  • Precentage of Participants with Adverse Events (AEs) [ Time Frame: Baseline to end of study (Week 192) ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures
 (submitted: May 10, 2018)
Change in smartphone-based Floodlight remote patient monitoring (RPM) Test Battery [ Time Frame: Baseline to Week 48 and baseline to end of study (Week 192) ]
Floodlight RPM Test Battery encompasses the following measures:
  • Information processing speed (IPS) test
  • Draw a Shape Test
  • Pinching Test
  • 2-Minute Walking test (2MWT)
  • U-Turn test (UTT)
  • Static balance test (SBT)
  • Continuous sensor-based passive Analysis of mobility and Gait-related motion (CAG)
  • Daily Mood Questions (DMQ)
  • Smartphone version of MSIS-29
  • MS Symptom Tracker (MSST)
During the first 48 weeks of the study, patient will be randomized according to the following two assessment groups to which patients will be randomly allocated in 3:1 ration:
  • Group 1 will receive a preconfigured and locked-in smartphone and will use the Floodlight RPM solution installed on the smartphone (n=450)
  • Group 2 will not receive a smartphone and will not use the Floodlight RPM solution (n=150) From Week 48 to 192, all study participants (n=600) will use the Floodlight RPM solution'
 
Descriptive Information
Brief Title  ICMJE A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
Official Title  ICMJE An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients With Progressive Multiple Sclerosis
Brief Summary This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Progressive Multiple Sclerosis (PMS)
Intervention  ICMJE Drug: Ocrelizumab
Ocrelizumab will be administered via intravenous (IV) infusion at an initial dose of two 300-mg infusions separated by 14 days (on Days 1 and 15), and then 600 mg at every subsequent dose every 24 weeks for the remainder of the study treatment period (approximately 192 weeks)
Study Arms  ICMJE Experimental: Ocrelizumab
Ocrelizumab will be administered via intravenous (IV) infusion.
Intervention: Drug: Ocrelizumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: November 25, 2022)
927
Original Estimated Enrollment  ICMJE
 (submitted: May 10, 2018)
600
Estimated Study Completion Date  ICMJE December 4, 2026
Estimated Primary Completion Date January 15, 2026   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Have a definite diagnosis of PMS (as per the revised McDonald 2010 criteria for PPMS or Lublin et al. 2014 criteria for PMS)
  • EDSS (Expanded Disability Status Scale) </ =6.5 at screening
  • Have a documented evidence of disability progression independent of relapse at any point over the 2 years prior to the screening visit. In case relapse(s) have occurred in the last 2 years, disability progression will have to be considered as independent of relapse activity as per treating physician's judgment
  • Fulfill at least one of the 21 criteria assessing the evidence of disability progression independent of relapse activity in the last 2 years using the pre-baseline disability progression rating system checklist
  • Have experience of having used a smartphone and connecting a smartphone to Wi-Fi network providers
  • For women of childbearing potential: agreement to remain abstinent or use acceptable contraceptive methods during the treatment period and for at least 6 months, or longer if the local label is more stringent after the last dose of study drug

Exclusion Criteria:

  • Relapsing-remitting multiple sclerosis (RRMS) at screening
  • Inability to complete an MRI
  • Gadolinium (Gd) intolerance
  • Known presence of other neurological disorders

Exclusions Related to General Health:

  • Pregnancy confirmed by positive serum β human chorionic gonadotropin (hCG) measured at screening
  • Lactation
  • Any concomitant disease that may require chronic treatment of systemic corticosteroids or immunosuppressants during the course of the study
  • History or currently active primary or secondary immunodeficiency
  • Lack of peripheral venous access
  • Significant or uncontrolled somatic disease or any other significant disease that may preclude participant from participating in the study.
  • Active infections must be treated and resolved prior to the first infusion of ocrelizumab
  • Participants in a severely immunocompromised state until the condition resolves
  • Participants with known active malignancies or being actively monitored for recurrence of malignancy
  • Participants who have or have had confirmed progressive multifocal leukoencephalopathy (PML)

Exclusions Related to Laboratory Findings:

  • Positive screening tests for hepatitis B
  • CD4 count <250/μL
  • ANC <1.0 × 103/μL
  • AST/SGOT or ALT/SGPT ≥3.0 × ULN in combination with either an elevated total bilirubin (>2 X ULN) or clinical jaundice

Exclusions Related to Medications:

  • Hypersensitivity to ocrelizumab or to any of its excipients
  • Previous treatment with ocrelizumab
  • Previous treatment with B-cell targeted therapies (i.e., atacicept, tabalumab, belimumab, ofatumumab, or obinutuzumab). Note: previous treatment with rituximab is allowed as long as the last dose was administered more than 6 months before the ocrelizumab infusion AND if discontinuation was due to adverse events or immunogenicity AND if Bcell levels are above the lower limit of normal (LLN) prior to screening.
  • Any previous treatment with alemtuzumab (Campath/Mabcampath/Lemtrada), total body irradiation, or bone marrow transplantation
  • Previous treatment with natalizumab where PML has not been excluded according to specific algorithm
  • Contraindications to or intolerance of oral or intravenous (IV) corticosteroids, including methylprednisolone administered IV, according to the country label
  • Systemic corticosteroid therapy within 4 weeks prior to screening
  • All vaccines should be given at least 6 weeks before the first infusion of ocrelizumab, unless the local regulations allow for a shorter interval. Live/live attenuated vaccines should be avoided during treatment and safety follow-up period until B cells are peripherally repleted
  • Previous treatment with daclizumab, ozanimod or figolimod in the last 8 weeks
  • Previous treatment with siponimod in the last 2 weeks
  • Treatment with fampridine/dalfampridine (Fampyra)/Ampyra) or other symptomatic MS treatment unless on stable dose for ≥30 days prior to screening
  • Previous treatment with natalizumab in the last 12 weeks.
  • Previous treatment with teriflunomide in the last 12 weeks. This washout period can be shortened if an accelerated elimination procedure is implemented before screening visit. One of the following elimination procedures can be used:
  • Cholestyramine 8 g administered 3 times daily for a period of at least 7 days (cholestyramine 4 g three times a day can be used, if cholestyramine 8 g three times a day is not well tolerated)
  • Alternatively, 50 g of activated powdered charcoal is administered every 12 hours for a period of at least 7 days.
  • Previous treatment with azathioprine, cyclophosphamide, mycophenolate mofetil or methotrexate in the last 12 weeks
  • Treatment with any investigational agent within 24 weeks of screening (Visit 1) or five half-lives of the investigational drug (whichever is longer) or treatment with any experimental procedures for MS
  • Previous treatment with mitoxantrone, cyclosporine or cladribine in the last 96 weeks
  • Participants previously treated with teriflunomide within the last two years, unless measured plasma concentrations are less than 0.02 mg/l. If above or not known, an accelerated elimination procedure should be implemented before screening visit
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Bosnia and Herzegovina,   Brazil,   Canada,   Colombia,   Costa Rica,   Czechia,   Denmark,   Egypt,   France,   Germany,   Guatemala,   Hungary,   Ireland,   Italy,   Lebanon,   Mexico,   Morocco,   Netherlands,   Panama,   Poland,   Russian Federation,   Spain,   United Arab Emirates,   United States
Removed Location Countries Algeria,   Saudi Arabia
 
Administrative Information
NCT Number  ICMJE NCT03523858
Other Study ID Numbers  ICMJE MN39159
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Current Responsible Party Hoffmann-La Roche
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Hoffmann-La Roche
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Clinical Trials Hoffmann-La Roche
PRS Account Hoffmann-La Roche
Verification Date January 2023

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP